JP2003520271A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520271A5 JP2003520271A5 JP2001553266A JP2001553266A JP2003520271A5 JP 2003520271 A5 JP2003520271 A5 JP 2003520271A5 JP 2001553266 A JP2001553266 A JP 2001553266A JP 2001553266 A JP2001553266 A JP 2001553266A JP 2003520271 A5 JP2003520271 A5 JP 2003520271A5
- Authority
- JP
- Japan
- Prior art keywords
- nonanoic acid
- amino
- pyrimidin
- alkyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 description 41
- -1 trifluoromethoxy, trifluoroethoxy Chemical group 0.000 description 32
- 239000000203 mixture Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 11
- 230000003042 antagnostic effect Effects 0.000 description 10
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- WDUCCRCCNFQPND-LURJTMIESA-N (2S)-2-(6-methoxypyridin-3-yl)propanoic acid Chemical compound COC1=CC=C(C=N1)[C@@H](C(=O)O)C WDUCCRCCNFQPND-LURJTMIESA-N 0.000 description 4
- WDUCCRCCNFQPND-ZCFIWIBFSA-N (2r)-2-(6-methoxypyridin-3-yl)propanoic acid Chemical compound COC1=CC=C([C@@H](C)C(O)=O)C=N1 WDUCCRCCNFQPND-ZCFIWIBFSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- QSXLNPJVCMDNMJ-LJQANCHMSA-N (2R)-2-(2-ethoxypyrimidin-5-yl)-9-[6-(ethylamino)pyridin-2-yl]nonanoic acid Chemical compound CCNc1cccc(CCCCCCC[C@@H](C(O)=O)c2cnc(OCC)nc2)n1 QSXLNPJVCMDNMJ-LJQANCHMSA-N 0.000 description 2
- KYFKMRYPDPIWTB-GOSISDBHSA-N (2R)-2-(2-ethoxypyrimidin-5-yl)-9-[6-(methylamino)pyridin-2-yl]nonanoic acid Chemical compound CCOc1ncc(cn1)[C@@H](CCCCCCCc1cccc(NC)n1)C(O)=O KYFKMRYPDPIWTB-GOSISDBHSA-N 0.000 description 2
- PEDHXPMFOQNWDK-QGZVFWFLSA-N (2R)-2-(2-methoxypyrimidin-5-yl)-9-[6-(methylamino)pyridin-2-yl]nonanoic acid Chemical compound CNc1cccc(CCCCCCC[C@@H](C(O)=O)c2cnc(OC)nc2)n1 PEDHXPMFOQNWDK-QGZVFWFLSA-N 0.000 description 2
- AWYWMTHHAQWPBM-MRXNPFEDSA-N (2R)-2-(2-methylpyrimidin-5-yl)-10-oxo-10-(1,4,5,6-tetrahydropyrimidin-2-ylamino)decanoic acid Chemical compound Cc1ncc(cn1)[C@@H](CCCCCCCC(=O)NC1=NCCCN1)C(O)=O AWYWMTHHAQWPBM-MRXNPFEDSA-N 0.000 description 2
- OPYCHDDDPARINO-IBGZPJMESA-N (2R)-2-quinolin-3-yl-3-[5-(1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)pentanoylamino]propanoic acid Chemical compound OC(=O)[C@@H](CNC(=O)CCCCc1ccc2NCCNc2n1)c1cnc2ccccc2c1 OPYCHDDDPARINO-IBGZPJMESA-N 0.000 description 2
- KDHUGBWGQNYIQB-GOSISDBHSA-N (2R)-9-[6-(ethylamino)pyridin-2-yl]-2-(2-methoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNc1cccc(CCCCCCC[C@@H](C(O)=O)c2cnc(OC)nc2)n1 KDHUGBWGQNYIQB-GOSISDBHSA-N 0.000 description 2
- QSXLNPJVCMDNMJ-IBGZPJMESA-N (2S)-2-(2-ethoxypyrimidin-5-yl)-9-[6-(ethylamino)pyridin-2-yl]nonanoic acid Chemical compound CCNc1cccc(CCCCCCC[C@H](C(O)=O)c2cnc(OCC)nc2)n1 QSXLNPJVCMDNMJ-IBGZPJMESA-N 0.000 description 2
- KYFKMRYPDPIWTB-SFHVURJKSA-N (2S)-2-(2-ethoxypyrimidin-5-yl)-9-[6-(methylamino)pyridin-2-yl]nonanoic acid Chemical compound CCOc1ncc(cn1)[C@H](CCCCCCCc1cccc(NC)n1)C(O)=O KYFKMRYPDPIWTB-SFHVURJKSA-N 0.000 description 2
- PEDHXPMFOQNWDK-KRWDZBQOSA-N (2S)-2-(2-methoxypyrimidin-5-yl)-9-[6-(methylamino)pyridin-2-yl]nonanoic acid Chemical compound CNc1cccc(CCCCCCC[C@H](C(O)=O)c2cnc(OC)nc2)n1 PEDHXPMFOQNWDK-KRWDZBQOSA-N 0.000 description 2
- AWYWMTHHAQWPBM-INIZCTEOSA-N (2S)-2-(2-methylpyrimidin-5-yl)-10-oxo-10-(1,4,5,6-tetrahydropyrimidin-2-ylamino)decanoic acid Chemical compound Cc1ncc(cn1)[C@H](CCCCCCCC(=O)NC1=NCCCN1)C(O)=O AWYWMTHHAQWPBM-INIZCTEOSA-N 0.000 description 2
- KDHUGBWGQNYIQB-SFHVURJKSA-N (2S)-9-[6-(ethylamino)pyridin-2-yl]-2-(2-methoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNc1cccc(CCCCCCC[C@H](C(O)=O)c2cnc(OC)nc2)n1 KDHUGBWGQNYIQB-SFHVURJKSA-N 0.000 description 2
- OPYCHDDDPARINO-LJQANCHMSA-N (2s)-2-quinolin-3-yl-3-[5-(1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)pentanoylamino]propanoic acid Chemical compound C1=CC=CC2=CC([C@@H](CNC(=O)CCCCC=3N=C4NCCNC4=CC=3)C(=O)O)=CN=C21 OPYCHDDDPARINO-LJQANCHMSA-N 0.000 description 2
- UEAARPQIXXQIAV-MRXNPFEDSA-N (3r)-3-(2-ethoxypyrimidin-5-yl)-9-[2-(ethylamino)pyrimidin-4-yl]nonanoic acid Chemical compound CCNC1=NC=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 UEAARPQIXXQIAV-MRXNPFEDSA-N 0.000 description 2
- GIWIXAZUOFJHSH-HXUWFJFHSA-N (3r)-3-[5-(3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazin-6-yl)pentanoylamino]-3-quinolin-3-ylpropanoic acid Chemical compound C1=CC=CC2=CC([C@H](NC(=O)CCCCC=3N=C4NCCOC4=CC=3)CC(=O)O)=CN=C21 GIWIXAZUOFJHSH-HXUWFJFHSA-N 0.000 description 2
- NDKSDRWJWLNIIF-QGZVFWFLSA-N (3r)-9-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-6-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](CC(O)=O)CCCCCCC1=CC=C(CCN2)C2=N1 NDKSDRWJWLNIIF-QGZVFWFLSA-N 0.000 description 2
- GYQWSGPGWQIRDK-CYBMUJFWSA-N (3r)-9-(2,6-diaminopyrimidin-4-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](CC(O)=O)CCCCCCC1=CC(N)=NC(N)=N1 GYQWSGPGWQIRDK-CYBMUJFWSA-N 0.000 description 2
- VEJIHHNAPVFTIX-OAHLLOKOSA-N (3r)-9-(2,6-diaminopyrimidin-4-yl)-3-quinolin-3-ylnonanoic acid Chemical compound NC1=NC(N)=CC(CCCCCC[C@H](CC(O)=O)C=2C=C3C=CC=CC3=NC=2)=N1 VEJIHHNAPVFTIX-OAHLLOKOSA-N 0.000 description 2
- WLGGRYVUWIAQNO-QGZVFWFLSA-N (3r)-9-[6-(ethylamino)pyridin-2-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=CC=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(C)=NC=2)=N1 WLGGRYVUWIAQNO-QGZVFWFLSA-N 0.000 description 2
- AJRXGUGHNUPKPA-MRXNPFEDSA-N (3r)-9-[6-(methylamino)pyridin-2-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CNC1=CC=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(C)=NC=2)=N1 AJRXGUGHNUPKPA-MRXNPFEDSA-N 0.000 description 2
- XAUMHHQRAGTYON-OAHLLOKOSA-N (3r)-9-[6-(methylamino)pyridin-2-yl]-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC=NC=2)=N1 XAUMHHQRAGTYON-OAHLLOKOSA-N 0.000 description 2
- PWXAAPNZAANJNH-QGZVFWFLSA-N (3r)-9-[6-(methylamino)pyridin-2-yl]-3-quinoxalin-2-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCCC[C@H](CC(O)=O)C=2N=C3C=CC=CC3=NC=2)=N1 PWXAAPNZAANJNH-QGZVFWFLSA-N 0.000 description 2
- IYVLNCGDRIBSON-QGZVFWFLSA-N (3r)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2,3-dihydro-1-benzofuran-6-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@H](CC(O)=O)C=2C=C3OCCC3=CC=2)=N1 IYVLNCGDRIBSON-QGZVFWFLSA-N 0.000 description 2
- GMBMWLGJYVBWPA-OAHLLOKOSA-N (3r)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-ethoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 GMBMWLGJYVBWPA-OAHLLOKOSA-N 0.000 description 2
- PUAXFUCQWQYYSP-CQSZACIVSA-N (3r)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-methoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(OC)=NC=2)=N1 PUAXFUCQWQYYSP-CQSZACIVSA-N 0.000 description 2
- JHVZPGUNRYRABX-OAHLLOKOSA-N (3r)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(C)=NC=2)=N1 JHVZPGUNRYRABX-OAHLLOKOSA-N 0.000 description 2
- APUMQXXPOIAIJC-OAHLLOKOSA-N (3r)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(6-methoxypyridin-3-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(OC)=CC=2)=N1 APUMQXXPOIAIJC-OAHLLOKOSA-N 0.000 description 2
- UEAARPQIXXQIAV-INIZCTEOSA-N (3s)-3-(2-ethoxypyrimidin-5-yl)-9-[2-(ethylamino)pyrimidin-4-yl]nonanoic acid Chemical compound CCNC1=NC=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 UEAARPQIXXQIAV-INIZCTEOSA-N 0.000 description 2
- GYCOITXBHQCENR-IBGZPJMESA-N (3s)-3-(2-methylpyrimidin-5-yl)-9-(6,7,8,9-tetrahydro-5h-pyrido[2,3-b]azepin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](CC(O)=O)CCCCCCC1=CC=C(CCCCN2)C2=N1 GYCOITXBHQCENR-IBGZPJMESA-N 0.000 description 2
- GYQWSGPGWQIRDK-ZDUSSCGKSA-N (3s)-9-(2,6-diaminopyrimidin-4-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](CC(O)=O)CCCCCCC1=CC(N)=NC(N)=N1 GYQWSGPGWQIRDK-ZDUSSCGKSA-N 0.000 description 2
- VEJIHHNAPVFTIX-HNNXBMFYSA-N (3s)-9-(2,6-diaminopyrimidin-4-yl)-3-quinolin-3-ylnonanoic acid Chemical compound NC1=NC(N)=CC(CCCCCC[C@@H](CC(O)=O)C=2C=C3C=CC=CC3=NC=2)=N1 VEJIHHNAPVFTIX-HNNXBMFYSA-N 0.000 description 2
- FPLIORKDZLLQPL-HNNXBMFYSA-N (3s)-9-[2-amino-6-(ethylamino)pyrimidin-4-yl]-3-(2-ethoxypyrimidin-5-yl)nonanoic acid Chemical compound NC1=NC(NCC)=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 FPLIORKDZLLQPL-HNNXBMFYSA-N 0.000 description 2
- WLGGRYVUWIAQNO-KRWDZBQOSA-N (3s)-9-[6-(ethylamino)pyridin-2-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=CC=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(C)=NC=2)=N1 WLGGRYVUWIAQNO-KRWDZBQOSA-N 0.000 description 2
- AJRXGUGHNUPKPA-INIZCTEOSA-N (3s)-9-[6-(methylamino)pyridin-2-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CNC1=CC=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(C)=NC=2)=N1 AJRXGUGHNUPKPA-INIZCTEOSA-N 0.000 description 2
- XAUMHHQRAGTYON-HNNXBMFYSA-N (3s)-9-[6-(methylamino)pyridin-2-yl]-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC=NC=2)=N1 XAUMHHQRAGTYON-HNNXBMFYSA-N 0.000 description 2
- PWXAAPNZAANJNH-KRWDZBQOSA-N (3s)-9-[6-(methylamino)pyridin-2-yl]-3-quinoxalin-2-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCCC[C@@H](CC(O)=O)C=2N=C3C=CC=CC3=NC=2)=N1 PWXAAPNZAANJNH-KRWDZBQOSA-N 0.000 description 2
- IYVLNCGDRIBSON-KRWDZBQOSA-N (3s)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2,3-dihydro-1-benzofuran-6-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@@H](CC(O)=O)C=2C=C3OCCC3=CC=2)=N1 IYVLNCGDRIBSON-KRWDZBQOSA-N 0.000 description 2
- PUAXFUCQWQYYSP-AWEZNQCLSA-N (3s)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-methoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(OC)=NC=2)=N1 PUAXFUCQWQYYSP-AWEZNQCLSA-N 0.000 description 2
- JHVZPGUNRYRABX-HNNXBMFYSA-N (3s)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(C)=NC=2)=N1 JHVZPGUNRYRABX-HNNXBMFYSA-N 0.000 description 2
- APUMQXXPOIAIJC-HNNXBMFYSA-N (3s)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(6-methoxypyridin-3-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(OC)=CC=2)=N1 APUMQXXPOIAIJC-HNNXBMFYSA-N 0.000 description 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 2
- 229940121819 ATPase inhibitor Drugs 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000004171 Cathepsin K Human genes 0.000 description 2
- 108090000625 Cathepsin K Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000002834 estrogen receptor modulator Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- FPLIORKDZLLQPL-OAHLLOKOSA-N (3r)-9-[2-amino-6-(ethylamino)pyrimidin-4-yl]-3-(2-ethoxypyrimidin-5-yl)nonanoic acid Chemical compound NC1=NC(NCC)=CC(CCCCCC[C@H](CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 FPLIORKDZLLQPL-OAHLLOKOSA-N 0.000 description 1
- GIWIXAZUOFJHSH-FQEVSTJZSA-N (3s)-3-[5-(3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazin-6-yl)pentanoylamino]-3-quinolin-3-ylpropanoic acid Chemical compound C1=CC=CC2=CC([C@@H](NC(=O)CCCCC=3N=C4NCCOC4=CC=3)CC(=O)O)=CN=C21 GIWIXAZUOFJHSH-FQEVSTJZSA-N 0.000 description 1
- NDKSDRWJWLNIIF-KRWDZBQOSA-N (3s)-9-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-6-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](CC(O)=O)CCCCCCC1=CC=C(CCN2)C2=N1 NDKSDRWJWLNIIF-KRWDZBQOSA-N 0.000 description 1
- GMBMWLGJYVBWPA-HNNXBMFYSA-N (3s)-9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-ethoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCC[C@@H](CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 GMBMWLGJYVBWPA-HNNXBMFYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 description 1
- AWYWMTHHAQWPBM-UHFFFAOYSA-N 2-(2-methylpyrimidin-5-yl)-10-oxo-10-(1,4,5,6-tetrahydropyrimidin-2-ylamino)decanoic acid Chemical compound C1=NC(C)=NC=C1C(C(O)=O)CCCCCCCC(=O)NC1=NCCCN1 AWYWMTHHAQWPBM-UHFFFAOYSA-N 0.000 description 1
- IWFKOKATFORZPN-UHFFFAOYSA-N 2-[5-(2,6-diaminopyrimidin-4-yl)pentanoyl-methylamino]-3-(6-methoxypyridin-3-yl)propanoic acid Chemical compound C1=NC(OC)=CC=C1CC(C(O)=O)N(C)C(=O)CCCCC1=CC(N)=NC(N)=N1 IWFKOKATFORZPN-UHFFFAOYSA-N 0.000 description 1
- XLQVCNQOYAVZTQ-UHFFFAOYSA-N 2-[5-(3-amino-5,6,7,8-tetrahydroisoquinolin-1-yl)pentanoyl-methylamino]-3-(6-methoxypyridin-3-yl)propanoic acid Chemical compound C1=NC(OC)=CC=C1CC(C(O)=O)N(C)C(=O)CCCCC1=NC(N)=CC2=C1CCCC2 XLQVCNQOYAVZTQ-UHFFFAOYSA-N 0.000 description 1
- UEAARPQIXXQIAV-UHFFFAOYSA-N 3-(2-ethoxypyrimidin-5-yl)-9-[2-(ethylamino)pyrimidin-4-yl]nonanoic acid Chemical compound CCNC1=NC=CC(CCCCCCC(CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 UEAARPQIXXQIAV-UHFFFAOYSA-N 0.000 description 1
- UIPWNMDREFCECM-UHFFFAOYSA-N 3-(2-ethoxypyrimidin-5-yl)-9-[6-(ethylamino)pyridin-2-yl]nonanoic acid Chemical compound CCNC1=CC=CC(CCCCCCC(CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 UIPWNMDREFCECM-UHFFFAOYSA-N 0.000 description 1
- GJVHCRVNERTQGJ-UHFFFAOYSA-N 3-(2-ethoxypyrimidin-5-yl)-9-[6-(methylamino)pyridin-2-yl]nonanoic acid Chemical compound C1=NC(OCC)=NC=C1C(CC(O)=O)CCCCCCC1=CC=CC(NC)=N1 GJVHCRVNERTQGJ-UHFFFAOYSA-N 0.000 description 1
- LHLSZKTUKMWFQV-UHFFFAOYSA-N 3-(2-methoxypyrimidin-5-yl)-9-[6-(methylamino)pyridin-2-yl]nonanoic acid Chemical compound CNC1=CC=CC(CCCCCCC(CC(O)=O)C=2C=NC(OC)=NC=2)=N1 LHLSZKTUKMWFQV-UHFFFAOYSA-N 0.000 description 1
- AFRWBHKDHBGCJZ-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-10-(1,4,5,6-tetrahydropyrimidin-2-ylamino)decanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CCCCCCCNC1=NCCCN1 AFRWBHKDHBGCJZ-UHFFFAOYSA-N 0.000 description 1
- GIWIXAZUOFJHSH-UHFFFAOYSA-N 3-[5-(3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazin-6-yl)pentanoylamino]-3-quinolin-3-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(NC(=O)CCCCC=3N=C4NCCOC4=CC=3)CC(=O)O)=CN=C21 GIWIXAZUOFJHSH-UHFFFAOYSA-N 0.000 description 1
- LUTBCWPINXUOLG-UHFFFAOYSA-N 3-pyrimidin-5-yl-9-(6,7,8,9-tetrahydro-5h-pyrido[2,3-b]azepin-2-yl)nonanoic acid Chemical compound C=1C=C2CCCCNC2=NC=1CCCCCCC(CC(=O)O)C1=CN=CN=C1 LUTBCWPINXUOLG-UHFFFAOYSA-N 0.000 description 1
- RYBXVUBVKWLRLI-UHFFFAOYSA-N 3-quinolin-3-yl-3-[5-(1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)pentanoylamino]propanoic acid Chemical compound C1=CC=CC2=CC(C(NC(=O)CCCCC=3N=C4NCCNC4=CC=3)CC(=O)O)=CN=C21 RYBXVUBVKWLRLI-UHFFFAOYSA-N 0.000 description 1
- NDKSDRWJWLNIIF-UHFFFAOYSA-N 9-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-6-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CCCCCCC1=CC=C(CCN2)C2=N1 NDKSDRWJWLNIIF-UHFFFAOYSA-N 0.000 description 1
- GYQWSGPGWQIRDK-UHFFFAOYSA-N 9-(2,6-diaminopyrimidin-4-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CCCCCCC1=CC(N)=NC(N)=N1 GYQWSGPGWQIRDK-UHFFFAOYSA-N 0.000 description 1
- VEJIHHNAPVFTIX-UHFFFAOYSA-N 9-(2,6-diaminopyrimidin-4-yl)-3-quinolin-3-ylnonanoic acid Chemical compound NC1=NC(N)=CC(CCCCCCC(CC(O)=O)C=2C=C3C=CC=CC3=NC=2)=N1 VEJIHHNAPVFTIX-UHFFFAOYSA-N 0.000 description 1
- FPLIORKDZLLQPL-UHFFFAOYSA-N 9-[2-amino-6-(ethylamino)pyrimidin-4-yl]-3-(2-ethoxypyrimidin-5-yl)nonanoic acid Chemical compound NC1=NC(NCC)=CC(CCCCCCC(CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 FPLIORKDZLLQPL-UHFFFAOYSA-N 0.000 description 1
- SKQDZNOTIPXFTR-UHFFFAOYSA-N 9-[6-(ethylamino)pyridin-2-yl]-3-(2-methoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=CC=CC(CCCCCCC(CC(O)=O)C=2C=NC(OC)=NC=2)=N1 SKQDZNOTIPXFTR-UHFFFAOYSA-N 0.000 description 1
- AJRXGUGHNUPKPA-UHFFFAOYSA-N 9-[6-(methylamino)pyridin-2-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CNC1=CC=CC(CCCCCCC(CC(O)=O)C=2C=NC(C)=NC=2)=N1 AJRXGUGHNUPKPA-UHFFFAOYSA-N 0.000 description 1
- XAUMHHQRAGTYON-UHFFFAOYSA-N 9-[6-(methylamino)pyridin-2-yl]-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCCCC(CC(O)=O)C=2C=NC=NC=2)=N1 XAUMHHQRAGTYON-UHFFFAOYSA-N 0.000 description 1
- PWXAAPNZAANJNH-UHFFFAOYSA-N 9-[6-(methylamino)pyridin-2-yl]-3-quinoxalin-2-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCCCC(CC(O)=O)C=2N=C3C=CC=CC3=NC=2)=N1 PWXAAPNZAANJNH-UHFFFAOYSA-N 0.000 description 1
- IYVLNCGDRIBSON-UHFFFAOYSA-N 9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2,3-dihydro-1-benzofuran-6-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCCC(CC(O)=O)C=2C=C3OCCC3=CC=2)=N1 IYVLNCGDRIBSON-UHFFFAOYSA-N 0.000 description 1
- GMBMWLGJYVBWPA-UHFFFAOYSA-N 9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-ethoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCCC(CC(O)=O)C=2C=NC(OCC)=NC=2)=N1 GMBMWLGJYVBWPA-UHFFFAOYSA-N 0.000 description 1
- PUAXFUCQWQYYSP-UHFFFAOYSA-N 9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-methoxypyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCCC(CC(O)=O)C=2C=NC(OC)=NC=2)=N1 PUAXFUCQWQYYSP-UHFFFAOYSA-N 0.000 description 1
- JHVZPGUNRYRABX-UHFFFAOYSA-N 9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(2-methylpyrimidin-5-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCCC(CC(O)=O)C=2C=NC(C)=NC=2)=N1 JHVZPGUNRYRABX-UHFFFAOYSA-N 0.000 description 1
- APUMQXXPOIAIJC-UHFFFAOYSA-N 9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-(6-methoxypyridin-3-yl)nonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCCC(CC(O)=O)C=2C=NC(OC)=CC=2)=N1 APUMQXXPOIAIJC-UHFFFAOYSA-N 0.000 description 1
- HDXFHKBRTKWMDO-UHFFFAOYSA-N 9-[6-amino-2-(ethylamino)pyrimidin-4-yl]-3-quinoxalin-2-ylnonanoic acid Chemical compound CCNC1=NC(N)=CC(CCCCCCC(CC(O)=O)C=2N=C3C=CC=CC3=NC=2)=N1 HDXFHKBRTKWMDO-UHFFFAOYSA-N 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- MMALNTHAZKZONC-ZDUSSCGKSA-N CCCCCCC[C@@H](C1=CN=C(N=C1)OCC)C(=O)O Chemical compound CCCCCCC[C@@H](C1=CN=C(N=C1)OCC)C(=O)O MMALNTHAZKZONC-ZDUSSCGKSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- STTGAPXAISJGRL-UJONTBEJSA-N NC1(NC(=CC=N1)CCCCCC[C@H](CC(=O)O)C=1C=NC(=NC1)OCC)NCC Chemical compound NC1(NC(=CC=N1)CCCCCC[C@H](CC(=O)O)C=1C=NC(=NC1)OCC)NCC STTGAPXAISJGRL-UJONTBEJSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 101100445392 Xenopus laevis ephb3 gene Proteins 0.000 description 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17779200P | 2000-01-24 | 2000-01-24 | |
| US60/177,792 | 2000-01-24 | ||
| US23046900P | 2000-09-06 | 2000-09-06 | |
| US60/230,469 | 2000-09-06 | ||
| PCT/US2001/001953 WO2001053262A1 (en) | 2000-01-24 | 2001-01-19 | Alpha v integrin receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003520271A JP2003520271A (ja) | 2003-07-02 |
| JP2003520271A5 true JP2003520271A5 (https=) | 2008-03-21 |
Family
ID=26873652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001553266A Withdrawn JP2003520271A (ja) | 2000-01-24 | 2001-01-19 | αｖインテグリン受容体拮抗薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6693101B2 (https=) |
| EP (1) | EP1254116A4 (https=) |
| JP (1) | JP2003520271A (https=) |
| AU (1) | AU780988B2 (https=) |
| CA (1) | CA2397665A1 (https=) |
| WO (1) | WO2001053262A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| CA2424304A1 (en) * | 2000-10-05 | 2002-04-11 | Merck & Co., Inc. | Process for preparation of integrin receptor antagonist intermediates |
| US20040030134A1 (en) * | 2001-10-01 | 2004-02-12 | Mcwilliams James Christopher | Process for preparation of integrin receptor antagonist intermediates |
| WO2003045367A1 (en) * | 2001-11-30 | 2003-06-05 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor |
| CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| AU2003217930A1 (en) * | 2002-03-04 | 2003-09-22 | Medimmune, Llc | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| US7276589B2 (en) | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| US7285268B2 (en) | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| JP2006516635A (ja) * | 2003-01-30 | 2006-07-06 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストの使用 |
| KR20070009637A (ko) | 2004-03-24 | 2007-01-18 | 피디엘 바이오파르마 인코포레이티드 | 암 세포 증식을 억제하는 항α5β1 항체의 용도 |
| ES2671522T3 (es) * | 2004-04-02 | 2018-06-06 | The Regents Of The University Of California | Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5 |
| KR101595238B1 (ko) | 2007-12-21 | 2016-02-18 | 리간드 파마슈티칼스 인코포레이티드 | 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도 |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| CA2767409C (en) | 2009-07-24 | 2018-10-30 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin |
| JP6321673B2 (ja) * | 2012-12-20 | 2018-05-09 | ルゥ チーン−ビン | 放射線と組み合わせて使用するための放射線増感剤化合物 |
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| HRP20171873T1 (hr) | 2013-02-07 | 2018-02-23 | Scifluor Life Sciences, Inc | Fluorinirani antagonisti integrina |
| PL3050878T3 (pl) * | 2013-09-24 | 2022-01-24 | Fujifilm Corporation | Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem |
| JP6357275B2 (ja) * | 2014-07-16 | 2018-07-11 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | ピッチ均一性を有したタイル状ｃｍｕｔダイ |
| WO2016029146A1 (en) * | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
| KR102647026B1 (ko) | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| ES2877707T3 (es) | 2015-03-25 | 2021-11-17 | Fujifilm Corp | Método para producir un nuevo compuesto que contiene nitrógeno o una sal del mismo, y producto intermedio de producción del mismo |
| WO2017160753A1 (en) * | 2016-03-14 | 2017-09-21 | The Penn State Research Foundation | Novel selenazolidine and thiazolidine compounds for treating cancer and other diseases |
| WO2017189828A1 (en) * | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| MA45918A (fr) | 2016-08-15 | 2019-06-19 | Bayer Ag | Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides |
| MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| FI3844162T3 (fi) | 2018-08-29 | 2025-03-27 | Morphic Therapeutic Inc | Alfa v beeta6 -integriinin estäjiä |
| AU2020257397B2 (en) | 2019-04-19 | 2026-02-26 | Ligand Pharmaceuticals Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5652363A (en) * | 1995-10-05 | 1997-07-29 | C.D. Searle & Co. | Pyrido-1,4-oxazinylalkyl-benzamide derivatives |
| US5952341A (en) | 1996-10-30 | 1999-09-14 | Merck & Co., Inc. | Integrin antagonists |
| US5872122A (en) * | 1997-10-16 | 1999-02-16 | Monsanto Company | Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| ES2241192T3 (es) * | 1997-12-17 | 2005-10-16 | MERCK & CO., INC. (A NEW JERSEY CORP.) | Antagonistas del receptor de integrina. |
| PT1187592E (pt) | 1999-06-02 | 2007-10-19 | Merck & Co Inc | Antagonistas dos receptores de integrina alfa v |
| US7015216B2 (en) * | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
-
2001
- 2001-01-19 EP EP01908643A patent/EP1254116A4/en not_active Withdrawn
- 2001-01-19 AU AU36488/01A patent/AU780988B2/en not_active Ceased
- 2001-01-19 CA CA002397665A patent/CA2397665A1/en not_active Abandoned
- 2001-01-19 WO PCT/US2001/001953 patent/WO2001053262A1/en not_active Ceased
- 2001-01-19 JP JP2001553266A patent/JP2003520271A/ja not_active Withdrawn
- 2001-01-23 US US09/767,471 patent/US6693101B2/en not_active Expired - Fee Related
-
2003
- 2003-07-10 US US10/618,414 patent/US7153862B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003520271A5 (https=) | ||
| JP2004500326A5 (https=) | ||
| CA2397194A1 (en) | Alpha v integrin receptor antagonists | |
| ES2974985T3 (es) | Inhibidores de FGFR y métodos de uso de los mismos | |
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| CN110267953B (zh) | 四氢咪唑并[4,5-c]吡啶衍生物作为pd-l1内在化诱导剂 | |
| CN105408312B (zh) | 喹啉衍生物 | |
| RU2013127577A (ru) | Замещенные 4-селенофен-2(или 3)-иламино)пиримидиновые соединения и способы их применения | |
| TW201822764A (zh) | Syk抑制劑 | |
| EP4334298A1 (en) | Urea derivatives which can be used to treat cancer | |
| US20210128723A1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| JP2020524717A (ja) | ヒトｓｔｉｎｇの小分子調節因子 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2002508326A5 (https=) | ||
| JP2018515570A (ja) | Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４ | |
| JP2017520607A5 (https=) | ||
| KR20150118102A (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 | |
| KR20200043439A (ko) | 치료 헤테로시클릭 화합물 | |
| KR20150083833A (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법 | |
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. | |
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| JP2017530154A5 (https=) | ||
| AR084067A1 (es) | Composiciones farmaceuticas | |
| CN120019054A (zh) | 取代四氢吡啶类化合物及其用途 | |
| WO2018153969A1 (en) | Combination of atr kinase inhibitors with radium-223 salt |